治疗方法：T1DM 的免疫疗法——针对固有免疫。
Therapy: Immunotherapy for T1DM--targeting innate immunity.
出版信息
Nat Rev Endocrinol. 2013 Jul;9(7):384-5. doi: 10.1038/nrendo.2013.103. Epub 2013 Jun 4.
Abstract
Moran et al report two trials of antagonism of the pro-inflammatory cytokine, IL-1, assessing the monoclonal antibody canakinumab and the IL-1 antagonist, anakinra in new-onset Type 1 Diabetes (T1D). The studies both showed that, although relatively safe, there was no efficacy in terms of halting decline in beta cell function. Is this the end of the line for targeting IL-1 in T1D?
摘要
莫兰等人报告了两项拮抗促炎细胞因子白细胞介素-1 (IL-1) 的试验，评估了单克隆抗体卡那单抗和白细胞介素-1 拮抗剂阿那白滞素在新发 1 型糖尿病 (T1D) 中的作用。这两项研究都表明，尽管相对安全，但在阻止β细胞功能下降方面没有疗效。这是否意味着针对 T1D 的白细胞介素-1 治疗的终点已经到来？
相似文献
1
Therapy: Immunotherapy for T1DM--targeting innate immunity.治疗方法：T1DM 的免疫疗法——针对固有免疫。
Nat Rev Endocrinol. 2013 Jul;9(7):384-5. doi: 10.1038/nrendo.2013.103. Epub 2013 Jun 4.
2
Immunomodulators: Cell savers.免疫调节剂：细胞回收器。
Nature. 2012 May 17;485(7398):S4-5. doi: 10.1038/485s4a.
3
Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation.抗 CD3 和白细胞介素-1 阻断协同逆转 NOD 小鼠 1 型糖尿病：免疫调节改善的证据。
Diabetes. 2012 Jan;61(1):145-54. doi: 10.2337/db11-1033. Epub 2011 Oct 31.
4
Targeting innate immunity in type 1 diabetes: strike one.针对1型糖尿病中的先天性免疫：一击。
Lancet. 2013 Jun 1;381(9881):1880-1. doi: 10.1016/S0140-6736(13)60257-3. Epub 2013 Apr 5.
5
Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.在疾病发作时进行的临床试验中，白细胞介素-1拮抗作用可缓解与1型糖尿病相关的炎症状态。
Eur J Immunol. 2016 Apr;46(4):1030-46. doi: 10.1002/eji.201546005. Epub 2016 Jan 21.
6
Anti-cytokine therapies in T1D: Concepts and strategies.1 型糖尿病的抗细胞因子治疗：概念与策略。
Clin Immunol. 2013 Dec;149(3):279-85. doi: 10.1016/j.clim.2013.02.003. Epub 2013 Feb 14.
7
Immunotherapy for Type 1 diabetes: getting beyond a negative first impression.1型糖尿病的免疫疗法：超越负面的第一印象。
Immunotherapy. 2012 Jul;4(7):655-8. doi: 10.2217/imt.12.54.
8
Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.全身型幼年特发性关节炎的并发症：危险因素及管理建议
Expert Rev Clin Immunol. 2015 May;11(5):575-88. doi: 10.1586/1744666X.2015.1032257. Epub 2015 Apr 4.
9
Human Vaccines & Immunotherapeutics: News.《人类疫苗与免疫疗法：新闻》
Hum Vaccin Immunother. 2018 Jan 2;14(1):9-10. doi: 10.1080/21645515.2018.1419757.
10
Targeting innate immunity for treatment of type 1 diabetes.靶向固有免疫治疗1型糖尿病。
Immunotherapy. 2014;6(12):1239-42. doi: 10.2217/imt.14.96.
引用本文的文献
1
Antidiabetic and Immunoregulatory Activities of Extract of L. in NOD with Spontaneous and Cyclophosphamide-Accelerated Diabetic Mice.山黧豆提取物对 NOD 自发性和环磷酰胺加速糖尿病小鼠的抗糖尿病和免疫调节作用。
Int J Mol Sci. 2023 Jun 8;24(12):9922. doi: 10.3390/ijms24129922.
2
CD4 T cell differentiation in type 1 diabetes.1型糖尿病中CD4 T细胞的分化
Clin Exp Immunol. 2016 Jan;183(1):16-29. doi: 10.1111/cei.12672. Epub 2015 Jul 28.
本文引用的文献
1
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.近期发病 1 型糖尿病的白细胞介素-1拮抗作用：两项多中心、随机、双盲、安慰剂对照试验。
Lancet. 2013 Jun 1;381(9881):1905-15. doi: 10.1016/S0140-6736(13)60023-9. Epub 2013 Apr 5.
2
The role of inflammasome-derived IL-1 in driving IL-17 responses.炎性小体衍生的白介素-1 在驱动白介素-17 反应中的作用。
J Leukoc Biol. 2013 Apr;93(4):489-97. doi: 10.1189/jlb.1012543. Epub 2012 Dec 27.
3
Apoptosis of human islet cells by cytokines.细胞因子诱导的人胰岛细胞凋亡。
Immune Netw. 2012 Jun;12(3):113-7. doi: 10.4110/in.2012.12.3.113. Epub 2012 Jun 30.
4
Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation.抗 CD3 和白细胞介素-1 阻断协同逆转 NOD 小鼠 1 型糖尿病：免疫调节改善的证据。
Diabetes. 2012 Jan;61(1):145-54. doi: 10.2337/db11-1033. Epub 2011 Oct 31.
5
In vivo diabetogenic action of CD4+ T lymphocytes requires Fas expression and is independent of IL-1 and IL-18.CD4+ T 淋巴细胞的体内致糖尿病作用需要 Fas 表达，并且不依赖于 IL-1 和 IL-18。
Eur J Immunol. 2011 May;41(5):1344-51. doi: 10.1002/eji.201041216. Epub 2011 Apr 13.
6
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.白细胞介素-1 在炎症性疾病发病机制和治疗中的作用。
Blood. 2011 Apr 7;117(14):3720-32. doi: 10.1182/blood-2010-07-273417. Epub 2011 Feb 8.
7
Blockade of interleukin 1 in type 1 diabetes mellitus.阻断白细胞介素-1治疗 1 型糖尿病。
Nat Rev Endocrinol. 2010 Mar;6(3):158-66. doi: 10.1038/nrendo.2009.271.
8
IL-1 receptor deficiency slows progression to diabetes in the NOD mouse.白细胞介素-1受体缺陷减缓非肥胖糖尿病小鼠向糖尿病的进展。
Diabetes. 2004 Jan;53(1):113-21. doi: 10.2337/diabetes.53.1.113.
9
Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.葡萄糖诱导的胰岛β细胞产生白细胞介素-1β会导致人类胰岛的糖毒性。
J Clin Invest. 2002 Sep;110(6):851-60. doi: 10.1172/JCI15318.
10
Role of pancreatic beta-cells in the process of beta-cell death.胰腺β细胞在β细胞死亡过程中的作用。
Diabetes. 2001 Feb;50 Suppl 1:S52-7. doi: 10.2337/diabetes.50.2007.s52.
Zotero 插件